IL-1b and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration

Journal of Immunology

Volumn 192, Issue 3, 2014, Pages 1277-1285

  Liang, Yong ^a,b   Ma, Shoubao ^a   Zhang, Yanming ^b,c   Wang, Ying ^c   Cheng, Qiao ^a   Wu, Yan ^a   Jin, Yue ^b   Zheng, Donghui ^b   Wu, Depei ^c   Liu, Haiyan ^a,c  

^a SOOCHOW UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ENDOTOXIN; INTERLEUKIN 1BETA; TOLL LIKE RECEPTOR 4; BORONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; TLR4 PROTEIN, MOUSE;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE EXACERBATION; ENZYME INHIBITION; IRRADIATION; MORBIDITY; MORTALITY; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIGNAL TRANSDUCTION; THERAPY DELAY; ACUTE DISEASE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GERMFREE ANIMAL; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; SPLEEN; WHOLE BODY RADIATION;

ACUTE DISEASE; ANIMALS; BONE MARROW TRANSPLANTATION; BORONIC ACIDS; CELL TRANSPLANTATION; CYCLOPHOSPHAMIDE; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEASE INHIBITORS; PYRAZINES; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; TOLL-LIKE RECEPTOR 4; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 84893410800     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203428     Document Type: Article

References (52)

1. Coghill, J. M., S. Sarantopoulos, T. P. Moran, W. J. Murphy, B. R. Blazar, and J. S. Serody. 2011. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 117: 3268-3276.
2. Sivula, J., Z. M. Cordova, J. Tuimala, T. Jaatinen, J. Partanen, L. Volin, and H. Turpeinen. 2012. Toll-like receptor gene polymorphisms confer susceptibility to graft-versus-host disease in allogenic hematopoietic stem cell transplantation. Scand. J. Immunol. 76: 336-341.
3. McCarthy, P. L., Jr., S. Abhyankar, S. Neben, G. Newman, C. Sieff, R. C. Thompson, S. J. Burakoff, and J. L. Ferrara. 1991. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78: 1915-1918.
4. Nestel, F. P., K. S. Price, T. A. Seemayer, and W. S. Lapp. 1992. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. 175: 405-413.
5. Baldwin, A. S., Jr. 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14: 649-683.
6. Martinon, F., and J. Tschopp. 2004. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117: 561-574.
7. Greten, F. R., M. C. Arkan, J. Bollrath, L. C. Hsu, J. Goode, C. Miething, S. I. Goktuna, M. Neuenhahn, J. Fierer, S. Paxian, et al. 2007. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130: 918-931.
8. Satou, Y., K. Nosaka, Y. Koya, J. I. Yasunaga, S. Toyokuni, and M. Matsuoka. 2004. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18: 1357-1363.
9. Sun, K., D. E. Wilkins, M. R. Anver, T. J. Sayers, A. Panoskaltsis-Mortari, B. R. Blazar, L. A. Welniak, and W. J. Murphy. 2005. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHDdependent gastrointestinal toxicity. Blood 106: 3293-3299.
10. Blanco, B., J. A. Pérez-Simón, L. I. Sánchez-Abarca, X. Carvajal-Vergara, J. Mateos, B. Vidriales, N. López-Holgado, P. Maiso, M. Alberca, E. Villarón, et al. 2006. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107: 3575-3583.
11. Koreth, J., K. E. Stevenson, H. T. Kim, M. Garcia, V. T. Ho, P. Armand, C. Cutler, J. Ritz, J. H. Antin, R. J. Soiffer, and E. P. Alyea, III. 2009. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 114: 3956-3959.
12. Sun, K., M. Li, T. J. Sayers, L. A. Welniak, and W. J. Murphy. 2008. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood 112: 1522-1529.
13. Cooke, K. R., A. Gerbitz, J. M. Crawford, T. Teshima, G. R. Hill, A. Tesolin, D. P. Rossignol, and J. L. Ferrara. 2001. LPS antagonism reduces graft-versushost disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J. Clin. Invest. 107: 1581-1589.
14. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
15. Hawn, T. R., H. Wu, J. M. Grossman, B. H. Hahn, B. P. Tsao, and A. Aderem. 2005. A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 102: 10593-10597.
16. Abdollahi-Roodsaz, S., L. A. Joosten, M. F. Roelofs, T. R. Radstake, G. Matera, C. Popa, J. W. van der Meer, M. G. Netea, and W. B. van den Berg. 2007. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum. 56: 2957-2967.
17. Pierik, M., S. Joossens, K. Van Steen, N. Van Schuerbeek, R. Vlietinck, P. Rutgeerts, and S. Vermeire. 2006. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm. Bowel Dis. 12: 1-8.
18. Dunn-Siegrist, I., P. Tissieres, G. Drifte, J. Bauer, S. Moutel, and J. Pugin. 2012. Toll-like receptor activation of human cells by synthetic triacylated lipid A-like molecules. J. Biol. Chem. 287: 16121-16131.
19. Elmaagacli, A. H., M. Koldehoff, H. Hindahl, N. K. Steckel, R. Trenschel, R. Peceny, H. Ottinger, P. M. Rath, R. S. Ross, M. Roggendorf, et al. 2006. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation 81: 247-254.
20. Turner, B. E., M. E. Kambouris, L. Sinfield, J. Lange, A. M. Burns, R. Lourie, K. Atkinson, D. N. Hart, D. J. Munster, and A. M. Rice. 2008. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Transplantation 86: 968-976.
21. Chiu, C. J., A. H. McArdle, R. Brown, H. J. Scott, and F. N. Gurd. 1970. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch. Surg. 101: 478-483.
22. Hill, G. R., K. R. Cooke, T. Teshima, J. M. Crawford, J. C. Keith, Jr., Y. S. Brinson, D. Bungard, and J. L. Ferrara. 1998. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102: 115-123.
23. Sun, K., L. A. Welniak, A. Panoskaltsis-Mortari, M. J. O'Shaughnessy, H. Liu, I. Barao, W. Riordan, R. Sitcheran, C. Wysocki, J. S. Serody, et al. 2004. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl. Acad. Sci. USA 101: 8120-8125.
24. Saperstein, S., H. Huyck, E. Kimball, C. Johnston, J. Finkelstein, and G. Pryhuber. 2009. The effects of interleukin-1beta in tumor necrosis factoralpha-induced acute pulmonary inflammation in mice. Mediators Inflamm. 2009: 958658.
25. Saperstein, S., L. Chen, D. Oakes, G. Pryhuber, and J. Finkelstein. 2009. IL-1beta augments TNF-Alpha-mediated inflammatory responses from lung epithelial cells. J. Interferon Cytokine Res. 29: 273-284.
26. Gerbitz, A., M. Schultz, A. Wilke, H. J. Linde, J. Scholmerich, R. Andreesen, and E. Holler. 2004. Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood 103: 4365-4367.
27. Sayers, T. J., A. D. Brooks, C. Y. Koh, W. Ma, N. Seki, A. Raziuddin, B. R. Blazar, X. Zhang, P. J. Elliott, and W. J. Murphy. 2003. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102: 303-310.
28. Koreth, J., K. E. Stevenson, H. T. Kim, S. M. McDonough, B. Bindra, P. Armand, V. T. Ho, C. Cutler, B. R. Blazar, J. H. Antin, et al. 2012. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J. Clin. Oncol. 30: 3202-3208.
29. Ferrara, J. L., J. E. Levine, P. Reddy, and E. Holler. 2009. Graft-versus-host disease. Lancet 373: 1550-1561.
30. Hill, G. R., and J. L. Ferrara. 2000. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95: 2754-2759.
31. Levine, J. E. 2011. Implications of TNF-A in the pathogenesis and management of GVHD. Int. J. Hematol. 93: 571-577.
32. Holler, E., H. J. Kolb, A. Moller, J. Kempeni, S. Liesenfeld, H. Pechumer, W. Lehmacher, G. Ruckdeschel, B. Gleixner, C. Riedner, et al. 1990. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75: 1011-1016.
33. Hill, G. R., T. Teshima, V. I. Rebel, O. I. Krijanovski, K. R. Cooke, Y. S. Brinson, and J. L. Ferrara. 2000. The p55 TNF-Alpha receptor plays a critical role in T cell alloreactivity. J. Immunol. 164: 656-663.
34. Brown, G. R., E. Lee, and D. L. Thiele. 2002. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J→C57BL/6J 3 bm12)F1 mice. J. Immunol. 168: 3065-3071.
35. Piguet, P. F., G. E. Grau, B. Allet, and P. Vassalli. 1987. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 166: 1280-1289.
36. Camussi, G., F. Bussolino, G. Salvidio, and C. Baglioni. 1987. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release plateletactivating factor. J. Exp. Med. 166: 1390-1404.
37. Hill, G. R., T. Teshima, A. Gerbitz, L. Pan, K. R. Cooke, Y. S. Brinson, J. M. Crawford, and J. L. Ferrara. 1999. Differential roles of IL-1 and TNF-Alpha on graft-versus-host disease and graft versus leukemia. J. Clin. Invest. 104: 459-467.
38. Chaudhry, S. I., S. Hooper, E. Nye, P. Williamson, K. Harrington, and E. Sahai. 2013. Autocrine IL-1b-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine TNFalpha signalling to carcinoma-Associated fibroblasts. Oncogene 32: 747-758.
39. Aida, Y., M. Maeno, N. Suzuki, A. Namba, M. Motohashi, M. Matsumoto, M. Makimura, and H. Matsumura. 2006. The effect of IL-1beta on the expression of inflammatory cytokines and their receptors in human chondrocytes. Life Sci. 79: 764-771.
40. Timoshanko, J. R., A. R. Kitching, Y. Iwakura, S. R. Holdsworth, and P. G. Tipping. 2004. Leukocyte-derived interleukin-1beta interacts with renal interleukin-1 receptor I to promote renal tumor necrosis factor and glomerular injury in murine crescentic glomerulonephritis. Am. J. Pathol. 164: 1967-1977.
41. Vallera, D. A., P. A. Taylor, J. L. Vannice, A. Panoskaltsis-Mortari, and B. R. Blazar. 1995. Interleukin-1 or tumor necrosis factor-Alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice. Transplantation 60: 1371-1374.
42. Antin, J. H., D. Weisdorf, D. Neuberg, R. Nicklow, S. Clouthier, S. J. Lee, E. Alyea, C. McGarigle, B. R. Blazar, S. Sonis, et al. 2002. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100: 3479-3482.
43. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529.
44. Diebold, S. S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
45. Lund, J. M., L. Alexopoulou, A. Sato, M. Karow, N. C. Adams, N. W. Gale, A. Iwasaki, and R. A. Flavell. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101: 5598-5603.
46. Lund, J., A. Sato, S. Akira, R. Medzhitov, and A. Iwasaki. 2003. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198: 513-520.
47. Boonstra, A., C. Asselin-Paturel, M. Gilliet, C. Crain, G. Trinchieri, Y. J. Liu, and A. O'Garra. 2003. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J. Exp. Med. 197: 101-109.
48. Brennan, T. V., L. Lin, X. Huang, D. M. Cardona, Z. Li, K. Dredge, N. J. Chao, and Y. Yang. 2012. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood 120: 2899-2908.
49. Cooke, K. R., G. R. Hill, J. M. Crawford, D. Bungard, Y. S. Brinson, J. Delmonte, Jr., and J. L. Ferrara. 1998. Tumor necrosis factor-Alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J. Clin. Invest. 102: 1882-1891.
50. Jackson, S. K., J. Parton, R. A. Barnes, C. H. Poynton, and C. Fegan. 1993. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur. J. Clin. Invest. 23: 540-545.
51. Fegan, C., C. H. Poynton, and J. A. Whittaker. 1990. The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant. 5: 373-377.
52. Poynton, C. H., S. Jackson, C. Fegan, R. A. Barnes, and J. A. Whittaker. 1992. Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplant. 9: 451-457.